{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:15:47Z","timestamp":1765545347186,"version":"3.41.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1990,6,1]],"date-time":"1990-06-01T00:00:00Z","timestamp":644198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1990,6,1]],"date-time":"1990-06-01T00:00:00Z","timestamp":644198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm Gen Sect"],"published-print":{"date-parts":[[1990,6]]},"DOI":"10.1007\/bf02260896","type":"journal-article","created":{"date-parts":[[2005,11,23]],"date-time":"2005-11-23T02:46:22Z","timestamp":1132713982000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Neuroleptic-induced catalepsy as a model of Parkinson's disease I. Effect of dopaminergic agents"],"prefix":"10.1007","volume":"2","author":[{"given":"P. J.","family":"Elliott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. P.","family":"Close","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. S.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1990,6,1]]},"reference":[{"key":"BF02260896_CR1","first-page":"434","volume":"64","author":"CD Andrews","year":"1978","unstructured":"Andrews CD, Woodruff GN (1978) Effect of the (+) and (\u2212) enantiomers of sulpiride on ADTN-induced hyperactivity in the rat. Br J Pharmacol 64: 434","journal-title":"Br J Pharmacol"},{"key":"BF02260896_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/0006-8993(86)91547-7","volume":"385","author":"SM Antleman","year":"1986","unstructured":"Antleman SM, Kocan D, Edwards DJ, Knopf S, Perel JM, Stiller R (1986) Behavioural effects of a single neuroleptic treatment grow with the passage of time. Brain Res 385: 58\u201367","journal-title":"Brain Res"},{"key":"BF02260896_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(89)92183-1","volume":"i","author":"R Barker","year":"1989","unstructured":"Barker R, Duncan J, Lees A (1989) Subcutaneous apomophine as a diagnostic test for dopaminergic responsivness in Parkinsonian syndromes. Lancet i: 675","journal-title":"Lancet"},{"key":"BF02260896_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1212\/WNL.37.10.1592","volume":"37","author":"P Barone","year":"1987","unstructured":"Barone P, Bankiewicz KS, Corsini GU, Kopin IJ, Chase TN (1987) Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology 37: 1592\u20131595","journal-title":"Neurology"},{"key":"BF02260896_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF01244638","volume":"68","author":"A Braun","year":"1986","unstructured":"Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1986) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68: 41\u201350.","journal-title":"J Neural Transm"},{"key":"BF02260896_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/0024-3205(84)90607-6","volume":"34","author":"AV Christensen","year":"1984","unstructured":"Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34: 1529\u20131540","journal-title":"Life Sci"},{"key":"BF02260896_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/syn.890010408","volume":"1","author":"D Clark","year":"1987","unstructured":"Clark D, White FJ (1987) Review: D 1 dopamine receptor \u2014 the search for a function: a critical evaluation of the D 1\/D 2 dopamine receptor classification and its functional implications. Synapse 1: 347\u2013388","journal-title":"Synapse"},{"key":"BF02260896_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1476-5381.1985.tb08863.x","volume":"85","author":"SP Close","year":"1985","unstructured":"Close SP, Marriott AS, Pay S (1985) Failure of SKF 38393A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Br J Pharmacol 85: 320\u2013322","journal-title":"Br J Pharmacol"},{"key":"BF02260896_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0028-3908(71)90053-0","volume":"10","author":"B Costall","year":"1971","unstructured":"Costall B, Olley JE (1971) Cholinergic- and neuroleptic-induced catalepsy: modification by lesions in the caudate-putamen. Neuropharmacology 10: 297\u2013306","journal-title":"Neuropharmacology"},{"key":"BF02260896_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev.ne.06.030183.000355","volume":"6","author":"I Creese","year":"1983","unstructured":"Creese I, Sibley DR, Hamblin MW, Leff SE (1983) The classification of dopamine receptors: relationship to radioligand binding. Ann Rev Neurosci 6: 43\u201371","journal-title":"Ann Rev Neurosci"},{"key":"BF02260896_CR11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/0028-3908(82)90082-X","volume":"21","author":"SB Dunnett","year":"1982","unstructured":"Dunnett SB, Iversen SD (1982) Spontaneous and drug-induced rotation following localized 6-hydroxydopamine and kainic acid-induced lesions of the neostriatum. Neuropharmacology 21: 899\u2013908","journal-title":"Neuropharmacology"},{"key":"BF02260896_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/0024-3205(88)90551-6","volume":"42","author":"B Ellenbroek","year":"1988","unstructured":"Ellenbroek B, Cools AR (1988) The paw test: an animal model for neuroleptic drugs which fulfills the criteria for pharmacological isomorphism. Life Sci 42: 1205\u20131213","journal-title":"Life Sci"},{"key":"BF02260896_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/0091-3057(86)90527-7","volume":"24","author":"PJ Elliott","year":"1986","unstructured":"Elliott PJ (1986) A reliable, rapid and inexpensive method for producing and implanting chronic cannulae into brains of small animals. Pharmacol Biochem Behav 24: 1809\u20131811","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02260896_CR14","first-page":"246","volume":"10","author":"R Fog","year":"1970","unstructured":"Fog R, Randrup A, Pakkenberg H (1970) Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped aggressive and cataleptic behaviour. Psychopharmacology 10: 246\u2013256","journal-title":"Psychopharmacology"},{"key":"BF02260896_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/oxfordjournals.bmb.a070990","volume":"29","author":"O Hornykiewicz","year":"1973","unstructured":"Hornykiewicz O (1973) Dopamine in the basal ganglia. Br Med Bull 29: 172\u2013178","journal-title":"Br Med Bull"},{"key":"BF02260896_CR16","first-page":"633","volume-title":"The neurobiology of dopamine","author":"O Hornykiewicz","year":"1979","unstructured":"Hornykiewicz O (1979) Brain dopamine in Parkinson's disease and other neurological disturbances. In: Horn AS, Korf J, Westerink BHC (eds) The neurobiology of dopamine. Academic Press, London, pp 633\u2013654"},{"key":"BF02260896_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1254\/jjp.27.397","volume":"27","author":"F Hondo","year":"1977","unstructured":"Hondo F, Satoh V, Shimomura K, Satoh H, Noguchi H, Uchida S, Kato R (1977) Dopamine receptor Glocking activity of sulpiride in the central nervous system. Jpn Pharmacol 27: 397\u2013411","journal-title":"Jpn Pharmacol"},{"key":"BF02260896_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4684-5191-7_2","volume-title":"Neurobiology of central D 1 dopamine receptors","author":"J Hytell","year":"1986","unstructured":"Hytell J, Arnt J (1986) Characterization of dopamine D1 and D2 receptors. In: Breese GR (ed) Neurobiology of central D 1 dopamine receptors. Plenum Press, New York, pp 15\u201328"},{"key":"BF02260896_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0091-3057(85)90091-7","volume":"23","author":"WR Klemm","year":"1985","unstructured":"Klemm WR (1985) Neuroleptic-induced catalepsy: a D-2 blockade phenomenon? Pharmacol Biochem Behav 23: 911\u2013915","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02260896_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0091-3057(88)90149-9","volume":"29","author":"WR Klemm","year":"1987","unstructured":"Klemm WR, Block H (1987) D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways. Pharmacol Biochem Behav 29: 223\u2013229","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02260896_CR21","first-page":"146","volume-title":"Movement disorders","author":"AN Liberman","year":"1982","unstructured":"Liberman AN, Goldstein M (1982) Treatment of advanced Parkinson's disease with dopamine agonists. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, p 146"},{"key":"BF02260896_CR22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/0024-3205(85)90159-6","volume":"36","author":"E Meller","year":"1985","unstructured":"Meller E, Kuga S, Friedhoff AJ, Goldstein M (1985) Selective D-2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D-1 antagonist. Life Sci 36: 1857\u20131864","journal-title":"Life Sci"},{"key":"BF02260896_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0014-2999(76)90302-2","volume":"35","author":"RJ Miller","year":"1976","unstructured":"Miller RJ, Kelly PH, Neumeyer JL (1976) Action of aporphine alkaloids on dopaminergic mechanisms in rat brain. Eur J Pharmacol 35: 77\u201383","journal-title":"Eur J Pharmacol"},{"key":"BF02260896_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0014-2999(85)90602-8","volume":"117","author":"M Morelli","year":"1985","unstructured":"Morelli M, Di Chiara G (1985) Catalepsy induced by SCH23390 in rats. Eur J Pharmacol 117: 179\u2013185","journal-title":"Eur J Pharmacol"},{"key":"BF02260896_CR25","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/0024-3205(79)90096-1","volume":"24","author":"CJE Niemegeers","year":"1979","unstructured":"Niemegeers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201\u20132216","journal-title":"Life Sci"},{"key":"BF02260896_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0304-3940(85)90037-0","volume":"57","author":"M Nomoto","year":"1985","unstructured":"Nomoto M, Jenner P, Marsden CD (1985) The dopamine D-2 agonist LY141865 but not the D-1 agonist SKF 38393 reverses parkinsonism induced by 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57: 37\u201341","journal-title":"Neurosci Lett"},{"key":"BF02260896_CR27","first-page":"242","volume":"82","author":"KM O'Boyle","year":"1984","unstructured":"O'Boyle KM, Pugh M, Waddington JL (1984) Stereotypy induced by the D-1 dopamine agonist RU24213 is blocked by the D-2 antagonist RO22-2586 and the D-1 antagonist SCH 23390. Br J Pharmacol 82: 242","journal-title":"Br J Pharmacol"},{"key":"BF02260896_CR28","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/0028-3908(87)90139-0","volume":"26","author":"KM O'Boyle","year":"1987","unstructured":"O'Boyle KM, Waddington JL (1987) New substituted 1-phenyl-3-benzazepine analogues of SKF 38393 and N-methyl-thienopyridine analogues of dihydroxynomifensine with selective affinity for the D-1 dopamine receptor in human post-mortem brain. Neuropharmacology 26: 1807\u20131810","journal-title":"Neuropharmacology"},{"key":"BF02260896_CR29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(89)92487-2","volume":"i","author":"W Poewe","year":"1989","unstructured":"Poewe W, Kleedorfer B, Wagner M, Berke T, Gasser T, Ooentel W (1989) Side effects of subcutaneous apomorphine in Parkinson's disease. Lancet i: 1084\u20131085","journal-title":"Lancet"},{"key":"BF02260896_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/284472a0","volume":"284","author":"PR Sanberg","year":"1980","unstructured":"Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284: 472\u2013473","journal-title":"Nature"},{"key":"BF02260896_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0893-133X(87)90004-2","volume":"1","author":"P Seeman","year":"1987","unstructured":"Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1: 5\u201315","journal-title":"Neuropsychopharmacology"},{"key":"BF02260896_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0028-3908(76)90115-5","volume":"15","author":"ME Stanley","year":"1976","unstructured":"Stanley ME, Glick SD (1976) Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15: 393\u2013394","journal-title":"Neuropharmacology"},{"key":"BF02260896_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/BF00216056","volume":"96","author":"AS Undie","year":"1988","unstructured":"Undie AS, Friedman E (1988) Difference in the cataleptogenic actions of SCH 23390 and selected classical neuroleptics. Psychopharmacology 96: 311\u2013316","journal-title":"Psychopharmacology"}],"container-title":["Journal of Neural Transmission - Parkinson's Disease and Dementia Section"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02260896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02260896\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02260896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02260896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:02:21Z","timestamp":1750791741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02260896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,6]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1990,6]]}},"alternative-id":["BF02260896"],"URL":"https:\/\/doi.org\/10.1007\/bf02260896","relation":{},"ISSN":["0936-3076"],"issn-type":[{"type":"print","value":"0936-3076"}],"subject":[],"published":{"date-parts":[[1990,6]]},"assertion":[{"value":"14 June 1989","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 1990","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 1990","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}